Text Size

Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma (acute asthma)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Richard Lockey, University of South Florida
ClinicalTrials.gov Identifier:
NCT01690793
First received: August 5, 2010
Last updated: September 18, 2012
Last verified: September 2012
History of Changes
  Purpose

The investigators hypothesize that there is a statistically significant decrease of Natriuretic Hormone Peptides (NHPs) in subjects with asthma exacerbation compared to levels following treatment of an exacerbation of asthma.


Condition
ASTHMA

Study Type: Observational
Official Title: Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

Resource links provided by NLM:

MedlinePlus related topics: Asthma
U.S. FDA Resources

Further study details as provided by University of South Florida:

Primary Outcome Measures:
  • The measurement of NHPs after treatment of an exacerbation of asthma [ Time Frame: 14 days ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius. GENETICS SAMPLES ARE OPTIONAL


Enrollment: 30
Study Start Date: February 2009
Study Completion Date: February 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Detailed Description:

Overall Study Design

  1. Measurement of Natriuretic Hormone Peptides in individuals suffering from exacerbation of asthma.
  2. Measurement of Natriuretic Hormone Peptides 5-7 days after initiation of treatment of exacerbation of asthma.
  3. Measurement of Natriuretic Hormone Peptides 10-14 days after initiation of treatment of exacerbation of asthma.

3 comparisons of Natriuretic Hormone Peptides levels will be made:

  1. Exacerbation compared to 5-7 days after initiation of treatment
  2. Exacerbation compared to 10-14 days after initiation of treatment
  3. 5-7 days after initiation of treatment compared to 10-14 days after initiation of treatment.

Samples of blood will be secured in the Division of Allergy/Immunology at the University of South Florida, Joy McCann Culverhouse Airways Disease Center. All samples will be appropriately coded to maintain confidentiality. Blood specimens will be held at minus 20 degrees Celsius.

  Eligibility

Ages Eligible for Study:   18 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

The Asthma Control Test score of less than 18.

Asthma control test consists of five questions, scored 1-5 each.

Criteria

Inclusion Criteria:

  • Both genders, age 18-85.
  • Females who are pregnant or lactating are not eligible.
  • Read and comprehend English.
  • Ability to give informed consent.
  • Seen in the outpatient setting at one of the clinic.
  • The subject must have a history of physician diagnosed asthma for at least 1 year and must have an exacerbation of asthma for entry into the study.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01690793

Locations
United States, Florida
Usf Asthma Allergy and Immunology Cru
Tampa, Florida, United States, 33613
Sponsors and Collaborators
University of South Florida
  More Information

No publications provided

Responsible Party: Richard Lockey, prinicpal investigator, University of South Florida
ClinicalTrials.gov Identifier: NCT01690793     History of Changes
Other Study ID Numbers: acute asthma
Study First Received: August 5, 2010
Last Updated: September 18, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of South Florida:
ASTHMA
ACUTE EXACERBATION OF ASTHMA

Additional relevant MeSH terms:
Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
 Immune System Diseases
Hormones
Natriuretic Agents
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Cardiovascular Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 13, 2013